Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06319443
Other study ID # STUDY00019235
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 26, 2024
Est. completion date April 2025

Study information

Verified date May 2024
Source Arizona State University
Contact Carol Johnston, PhD
Phone 6024962539
Email carol.johnston@asu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

When linking dietary interventions and blood glucose management, much of the existing research - particularly studies exploring the effects of vinegar - has relied on discrete readings from the conventional testing methods: blood samples or glucometers. These methods lack the capacity to provide insights into blood glucose dynamics 24/7. Recognizing this gap, the current study aims to utilize continuous glucose monitoring to examine the impact of daily vinegar ingestion on glucose variability in adults identified as glucose intolerant.


Description:

Participants are randomly assigned to either Group A or Group B using the Microsoft Excel randomization function. Group A will be instructed to consume 4 tablespoons of red wine vinegar (2 tablespoons diluted in water at the start of the lunch and the dinner meals) for the first 4 days of the trial. Conversely, participants in Group B will ingest the placebo for the initial 4 days, ingesting one pill daily upon waking in the morning. On days 5-9, participants will switch to the opposite treatment. The red wine vinegar dosage (4 tablespoons containing 3.5 g acetic acid - this is the amount of acetic acid in a large 4-inch dill pickle), and the placebo vinegar pill dosage (one pill containing 0.022 g acetic acid) will be taken daily during the trial. On visit 1, anthropometric measurements, including height, weight, and body composition (lean fat mass and body fat mass), will be measured, and the continuous glucose monitor will be placed on the upper arm. The participants will be instructed to fast >8 hours (no food or beverages with the exception of water) ahead of visit 1. To ensure accurate use and data collection, researchers discussed the operation of CGM devices and that these waterproof devices are to be continuously worn during the entire 9-day trial and will be removed on day 9 (visit 2).


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date April 2025
Est. primary completion date June 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - glucose intolerance (defined as one of the following: fasting glucose >99 mg/dl; diagnosis of prediabetes or diabetes; history of gestational diabetes) - 18 years of age or older - sedentary or moderately active (defined as a score = 24 on the Godin-Shepard Leisure Time Physical Activity Questionnaire) Exclusion Criteria: - currently adhering to a non-typical diet that would impact carbohydrate intake (including weight loss diets) - medication/drug use that has not been consistent for the previous 3 months or will be discontinued during the trial - any acute illness - regular smokers, pregnant or lactating women, or individuals taking insulin - Unwilling to tolerate vinegar ingestion

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Liquid vinegar
3.5 g acetic acid
vinegar pill
0.022 g acetic acid

Locations

Country Name City State
United States 850 PBC Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
Arizona State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average glucose The average blood glucose concentration for each 4-day period Four days
Primary Glucose: time in range The average time over 4 days that blood glucose falls in the reference range Four days
See also
  Status Clinical Trial Phase
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT03675360 - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial N/A
Completed NCT01671293 - Multicomponent Telecare Model for Supporting Prediabetes Patients N/A
Not yet recruiting NCT01402362 - Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study. N/A
Completed NCT00740363 - Sitagliptin in Renal Transplant Recipients Phase 4
Completed NCT00436475 - Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes Phase 1/Phase 2
Completed NCT04090788 - The Effect of Momordica Charantia Supplementation on Blood Glucose Levels N/A
Active, not recruiting NCT05460884 - Effects of Seaweed Extract on Postprandial Response to White Bread N/A
Not yet recruiting NCT05462834 - Impact of Nocturnal Hypoxemia on Glucose in High Altitude Sleep Disordered Breathing N/A
Completed NCT03348020 - Iron and Insulin Resistance in Overweight and Obese Humans N/A
Terminated NCT03356873 - Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX) N/A
Completed NCT03922685 - Effects of Diet and Exercise on Circadian Glycemia N/A
Completed NCT03730727 - Exercise-meal Timing and Postprandial Glucose Control N/A
Completed NCT04743960 - Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition N/A
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Terminated NCT01887691 - Sleep Effectiveness and Insulin and Glucose Homeostasis Phase 1
Completed NCT02412995 - The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite Phase 0
Not yet recruiting NCT01436448 - Probiotics (Lactobacillus Rhamnosus) in Reducing Glucose Intolerance During and After Pregnancy Phase 3